Egetis Therapeutics AB (publ) (LON:0ABW)

London flag London · Delayed Price · Currency is GBP · Price in SEK
4.985
-0.175 (-3.39%)
At close: Feb 11, 2026
Market Cap163.66M +2.1%
Revenue (ttm)4.37M -18.4%
Net Income-26.31M
EPS-0.07
Shares Outn/a
PE Ration/a
Forward PE11.63
Dividendn/a
Ex-Dividend Daten/a
Volume2,782
Average Volume21,791
Open5.000
Previous Close5.160
Day's Range4.965 - 5.000
52-Week Range3.105 - 6.870
Beta1.13
RSI48.87
Earnings DateFeb 26, 2026

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ... [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 40
Stock Exchange London Stock Exchange
Ticker Symbol 0ABW
Full Company Profile

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.

Financial numbers in SEK Financial Statements